Alvenex

Quick links to important sections

Alvenex

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Alvenex

Quick Facts

Property Description
Active ingredient Diosmin
Form Tablet, Capsule (Oral Administration)
Pharmacological class Phlebotonic Agent / Venoactive Drug
Origin Naturally derived bioflavonoid (from Citrus species)
Key Feature Often Micronized for enhanced absorption

What is Alvenex and its Pharmacological Class?

Alvenex is a specific trade name for a medicine containing the active substance Diosmin, which is fundamentally classified as a venoactive drug and a phlebotonic agent. This places the medicine in a category of compounds used to protect the vascular system and improve venous function. The compound is officially categorized as a Capillary Stabilizing Agent under the code WHO-ATC C05CA03. Alvenex is typically marketed for oral administration in the form of a tablet or capsule, ensuring systemic distribution throughout the entire venous network.

Composition: Diosmin, a Distinctive Flavone Glycoside

The key active ingredient is Diosmin, chemically defined as a flavone glycoside and a type of bioflavonoid. Diosmin is obtained from naturally occurring sources, being primarily derived from its precursor, Hesperidin, found in citrus fruits. A distinctive feature of this formulation is that the Diosmin preparation is typically processed into a highly refined, micronized form. This process is recognized for significantly enhancing the compound's intestinal absorption and subsequent bioavailability, optimizing the delivery of the active agent for improved vascular effects.

General Purpose of Venoactive Agents

The primary role of Alvenex, defined by its phlebotonic class, is to provide direct support to the body's vascular system. It operates by strengthening the walls of the veins to improve their venous tone and by reducing abnormal capillary permeability. The substance is recognized for its established vascular protective activity. This stabilizing action on the vascular structure defines its general purpose in reducing feelings of heaviness or discomfort by mitigating congestion associated with compromised venous return and capillary fragility.

What side effects are possible with Alvenex?

Possible Side Effects and Safety Information

The safety profile for Alvenex (Diosmin) is based on the classification of adverse reactions as documented in official government regulatory labels. These effects are grouped by their frequency and the system-organ-class (SOC) they affect.

Frequency-Classified Adverse Reactions

The most frequent adverse effects are classified as Common and are typically related to the Gastrointestinal disorders system, including diarrhoea, dyspepsia, nausea, and vomiting. Less frequent reactions classified as Rare may involve the Nervous system (e.g., headaches, dizziness) or the Skin and subcutaneous tissue disorders (e.g., rash, pruritus).

Classification Examples of Reactions (SOC)
Common Diarrhoea, Dyspepsia, Nausea, Vomiting (Gastrointestinal)
Rare Dizziness, Headaches (Nervous system); Rash, Urticaria (Skin)
Frequency not known Abdominal pain (Gastrointestinal); Quincke's oedema (Skin)

Safety Constraints and Special Populations

Official labels describe safety restrictions related to certain populations. Use of the medicine is not recommended during lactation due to insufficient data regarding its excretion into human milk. As a precautionary measure, use during pregnancy is typically avoided because of limited human data, though animal studies have not shown toxicity. The medication is contraindicated for individuals with known hypersensitivity to the active substance or any of its excipients. While no clinically relevant drug interactions have been reported to date, safety profiles indicate a negligible influence on the ability to drive or use machinery.

The overall safety structure of Alvenex is primarily defined by the concentration of Common effects in the digestive tract and explicit constraints on its use in special populations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents concerning over-usage of Alvenex (Diosmin) consistently state that clinical experience with overdose cases is limited. The documented manifestations of taking excessive amounts are generally confined to specific, non-severe effects, as regulatory labeling indicates that over-usage may primarily intensify the known side effects. No specific antidote is known or documented in official regulatory materials, and no severe or life-threatening systemic outcomes, such as specific cardiac or neurological complications, have been explicitly listed in the overdose sections.

Documented Overdose Manifestations

The most frequently reported manifestations in cases of over-usage are confined to two physiological systems:

  • Gastrointestinal System: Includes symptoms such as nausea, abdominal pain, and diarrhea.
  • Integumentary System (Skin): Includes manifestations such as rash and pruritus (itching).

Mandated Emergency Action

Regulatory authorities mandate clear, immediate action when over-usage occurs. It is officially required to seek medical attention immediately following any overdose event. The official instruction is to contact your doctor or pharmacist immediately for guidance. The mandated procedure for managing an overdose consists solely of providing systematic and supportive care aimed at treating the clinical signs and symptoms that present, without specific requirements for hospital monitoring or observation protocols being officially documented.

Therapeutic Uses of Alvenex

What Alvenex Treats: Main Uses and Benefits

Alvenex is a pharmacological treatment primarily utilized for the management of symptoms associated with chronic venous insufficiency and acute hemorrhoidal disease. It belongs to a class of medications known as vasoprotectors and venotonics, which are designed to improve vascular health.

Chronic Venous Insufficiency (CVI)

Chronic venous insufficiency occurs when the venous wall or valves in the leg veins do not work effectively, making it difficult for blood to return to the heart from the limbs. Alvenex is indicated to address the various clinical manifestations of this condition, including:

  • Lower Limb Heaviness: Reducing the sensation of weight and fatigue in the legs, which often worsens at the end of the day or after prolonged standing.
  • Pain and Cramping: Alleviating aching or discomfort in the lower extremities.
  • Edema: Managing the swelling of the lower legs and ankles caused by fluid accumulation.
  • Functional Recovery: Improving overall mobility by stabilizing venous tone and reducing the impact of circulatory sluggishness.

Hemorrhoidal Disease

Alvenex is also used for the symptomatic treatment of hemorrhoids, which are swollen veins in the lower rectum and anus. The medication is applied in two primary contexts:

  • Acute Hemorrhoidal Attacks: Providing relief from the sudden onset of pain, swelling, and inflammation during an acute episode.
  • Chronic Hemorrhoidal Symptoms: Assisting in the long-term management of recurring discomfort and vascular sensitivity in the anal region.

Mechanism of Action and Benefits

The therapeutic benefits of Alvenex are derived from its ability to influence the microcirculation and the venous system. The primary physiological advantages include:

  • Increased Venous Tone: It enhances the contraction of the venous walls, which helps move blood more efficiently and reduces venous stasis (pooling).
  • Microvascular Protection: It increases capillary resistance and decreases capillary permeability, which prevents excess fluid from leaking into surrounding tissues.
  • Anti-inflammatory Effects: It helps inhibit the inflammatory response at the vascular level, protecting the valves and vessel walls from damage.

Regulatory References

  1. Hungarian National Institute of Pharmacy and Nutrition Public Assessment Report

Eligibility and Restrictions for Use

Who Can and Cannot Use Alvenex? Official Eligibility

The eligibility for Alvenex (Diosmin) is strictly defined by regulatory authorities based on age, physiological state, and known allergies, detailing who is permitted to use the medicine and who is excluded.


Eligibility Scope

The primary population permitted to use the medicine are adults (18 years and older) in the absence of absolute non-eligibility factors. Use is formally contraindicated in any patient with known hypersensitivity or allergy to the active substance, Diosmin, or to any of the product's components, as documented in the official prescribing information.


Age and Condition Restrictions

The medicine is not recommended for the pediatric population (children and adolescents under 18 years). This exclusion is due to a lack of established safety and efficacy data for this age group in regulatory submissions.

Use is preferably avoided or considered inadvisable for women who are pregnant or breastfeeding. This restriction is a precautionary measure stemming from insufficient or limited data regarding the safety profile for the fetus or infant during these periods, as noted in official regulatory documents. Specific contraindications based on renal or hepatic impairment are generally not explicitly listed as absolute exclusions in the core labeling, but individuals should adhere to their health professional's guidance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Alvenex is primarily defined by the absence of documented, clinically relevant interactions with other medicinal products. This classification is based on accumulated post-marketing experience and review of available clinical data as assessed by national health authorities.

Regulatory documents formally note that no cases of significant drug-drug interaction have been reported since the marketing of the product. This finding dictates that the official labeling does not classify any medicinal products or substance categories as contraindicated solely due to an interaction risk.


Official Interaction Constraints

The official documentation provides specific constraints related to various interaction categories:

  • Pharmacokinetic Interactions: The prescribing information confirms that dedicated studies designed to assess potential pharmacokinetic interactions, such as those involving metabolic enzymes or drug transporters (e.g., CYP enzymes), have not been formally conducted for the active ingredient. Consequently, no specific enzyme inhibition or induction effects are officially recognized or cited in the labeling.

  • Timing and Restrictions: Due to the absence of reported interactions, the regulatory label does not impose mandatory timing separation requirements, nor does it list specific medicinal products that must be avoided or co-administered with caution based on interaction concerns.

  • Food and Supplements: The product information for Alvenex contains no specific prohibitions or warnings regarding the co-consumption of food, alcohol, herbal products, or other dietary supplements. This indicates that their co-use does not require specific, officially documented administration adjustments.

Mechanism of Action

Enhanced Venous Tone through Adrenergic Modulation

The primary mechanism involves modulating the post-synaptic alpha-adrenergic receptors on venous smooth muscle. Diosmin acts as an indirect inhibitor of the enzyme Catechol-O-methyltransferase (COMT), which prolongs the activity of the natural vasoconstrictor norepinephrine. This molecular effect leads to a physiological increase in venous smooth muscle Ca^2+ sensitivity, resulting in sustained venoconstriction . This action reduces venous compliance and limits blood accumulation, promoting venous return.

Stabilizing the Microcirculation and Capillary Integrity

Diosmin engages a vascular protective mechanism by stabilizing the capillary walls. It limits the adhesion and migration of leukocytes by inhibiting the expression of endothelial adhesion molecules. This attenuates the impact of inflammatory cells on the vessel lining, which, along with the drug's inherent antioxidant properties, supports endothelial stability. The resulting physiological effect is a reduction in capillary permeability and the restriction of fluid and plasma leakage into the surrounding tissue.

Boosting Lymphatic Drainage and Fluid Clearance

The mechanism extends to the lymphatic system, where the drug promotes improved fluid dynamics. Diosmin enhances the contractility of lymphatic collector vessels, increasing both the frequency and amplitude of their contractions. This effect increases the lymphatic system's capacity to transport interstitial fluid, thereby improving tissue fluid clearance and contributing to the regulation of fluid volume mediated by the vascular mechanisms.

Dosage and Administration Information

How to Use Alvenex: Official Administration Guidelines

Alvenex, which contains the active substance Diosmin, is administered following established protocols to ensure correct usage. The fundamental administration procedure is through the oral route as a film-coated tablet or capsule.


Official Dosing Regimens

Usage patterns are structurally separated based on the clinical context, defining either a long-term maintenance approach or a short, intensive course.

Context of Use Daily Dose (Micronized Purified Flavonoid Fraction) Frequency and Duration
Chronic Venous Insufficiency (CVI) 1000 mg per day. Taken once daily or in divided doses (500 mg twice daily) as part of a long-term plan.
Acute Hemorrhoidal Attack Days 1–4: 3000 mg per day.
Days 5–7: 2000 mg per day.
Structured 7-day course, administered in divided doses (2 to 3 times per day) to manage the high daily dose.

Administration Conditions and Handling

The medicine is instructed to be taken at mealtimes (with food). This condition standardizes the intake setting. If a dose is missed, the missed dose is skipped if it is near the time for the next dose, and the dose must never be doubled.

For some tablet forms with a score line, this line is only present to facilitate swallowing and is not intended for dividing the tablet to adjust the dosage. Furthermore, use of the medication is generally not recommended for children and adolescents.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence on Clinical Efficacy

Research has studied Corticostatil in chronic inflammatory joint conditions, with respect to measures of pain and inflammation. Studies evaluated whether the compound could affect disease progression and symptom severity in adult participants with confirmed diagnoses.

A large-scale randomized controlled trial (RCT) reported that patients receiving Corticostatil had lower disease activity scores compared to placebo. The primary endpoint measured in this study was the mean change in the Disease Activity Score-28 (DAS28) from baseline. Results from this study indicated that the difference in scores between the groups was noted by the four-week mark.


Corticostatil Use in Long-Term Studies

Safety data for Corticostatil were collected and analyzed in follow-up studies. Studies evaluating long-term use of Corticostatil, up to two years, did not find an increased incidence of serious cardiovascular events in the treatment group compared to the control group.

A two-year observational cohort study also assessed the impact on bone mineral density (BMD). Findings showed that the mean change in BMD did not differ significantly between the treatment group and the control group over the study period.


Studies on Combination Use

Studies have evaluated whether combining Corticostatil with standard physiotherapy may influence functional capacity in severe cases. These studies used the Health Assessment Questionnaire-Disability Index (HAQ-DI) as a primary measure.

Research examined the effect of the combination on joint stiffness and its association with the time required for participants to resume daily activities. The study protocols for combination therapy often involved a minimum of three sessions of physiotherapy per week alongside the administered drug dose.

Key Studies & References

  1. The Effect of Corticosteroid and Physical Therapy Combination on Functional Capacity and Joint Stiffness: A Randomized Controlled Trial
  2. National Institute for Health and Care Excellence (NICE): Rheumatoid Arthritis in Adults: Management - Clinical Guideline

Frequently Asked Questions (FAQ)

Common questions about Alvenex (FAQ)

Q: Why do people say they feel tired when they first start taking Alvenex?

Tiredness or fatigue is not listed as one of the common or rare adverse reactions in official regulatory safety documents for the active ingredient. However, related effects that involve the nervous system, such as headaches and dizziness, have been reported as rare adverse reactions.

Q: Is it normal to have a slight headache when starting Alvenex?

Headaches have been reported as a rare adverse reaction in official safety documents. Regulatory descriptions suggest that most reported side effects are generally temporary and tend to resolve once the medicine is stopped.

Q: What if I accidentally miss a day of taking Alvenex?

If a dose is missed and the next scheduled dose is approaching, the regulatory guidance is to skip the missed dose and continue with the usual schedule. Official patient information indicates that a double dose is not recommended to make up for a missed dose.

Q: Can Alvenex cause sleep problems or insomnia?

Official safety summaries do not explicitly list sleep problems or insomnia among the common or rare adverse reactions. However, adverse reactions that affect the nervous system, such as dizziness and headache, have been noted.

Q: Is Alvenex safe to use during pregnancy or while breastfeeding?

Official documents state that the use of the medicine is preferably avoided during pregnancy and is not recommended during lactation (breastfeeding). These are precautionary measures taken due to limited or insufficient data regarding the safety profile for the fetus or infant during these periods.

Q: If Alvenex causes dizziness, is that something that usually goes away?

Dizziness is reported in official documents as a rare adverse reaction. Regulatory descriptions suggest that most reported side effects are temporary and generally resolve when the medicine is discontinued.

Q: Does Alvenex affect blood pressure?

Official regulatory safety summaries do not list changes in blood pressure, either high (hypertension) or low (hypotension), as a common or rare adverse reaction in humans.

Q: How quickly should someone expect to feel the effects of Alvenex?

The benefits for vein-related issues are commonly seen within 2 to 3 weeks after beginning treatment. However, official information indicates that the full therapeutic effect may take 1 to 2 months to become apparent.

Q: Can Alvenex be taken with common pain relievers like ibuprofen?

Regulatory reviews indicate that no cases of clinically significant drug-drug interaction have been reported since the product's marketing. Consequently, official labeling does not list specific medicines, including common pain relievers, that must be avoided or co-administered with caution.

Q: How long does Alvenex stay in your system?

The active ingredient, Diosmin, is not detected in the bloodstream. It is quickly broken down into its active form, Diosmetin, which is then extensively processed by the body before being cleared.

Q: Are there any long-term effects associated with taking Alvenex for many years?

Studies and official information indicate that this medicine is sometimes used for long-term maintenance therapy for chronic venous conditions. Toxicity studies in animals have not shown pathological changes during long-term administration periods.

Q: Is Alvenex typically taken for a short time or long term?

The treatment duration varies significantly depending on the condition being addressed, according to regulatory dosing regimens. The medicine is used for time-limited, intensive courses for acute issues and for long-term chronic therapy for ongoing conditions.

Q: What are the eligibility requirements for someone to be prescribed Alvenex?

The medicine is officially used for the management of venous diseases. This includes addressing symptoms of chronic venous insufficiency, such as heavy legs or pain, and for the treatment of acute hemorrhoidal attacks.

Q: Does Alvenex have a risk of dependence or withdrawal symptoms?

The medicine is not classified as a controlled substance under federal drug schedules. Official documentation for the active ingredient does not cite a risk of dependence or withdrawal symptoms.

Q: What kind of studies or research has been done on Alvenex?

Research includes Randomized, Double-Blind, Placebo-Controlled Trials that have examined the efficacy and safety of the active ingredient. These studies focused primarily on subjects with Chronic Venous Disease.

Q: How is Alvenex different from a placebo in clinical trials?

Clinical trials, including randomized, placebo-controlled studies, have shown that the active ingredient produces a statistically significant improvement. This includes favorable changes in measures such as leg edema, pain scores, and overall disease severity compared to a placebo.

Q: Does Alvenex interact with common supplements like multivitamins or herbal remedies?

Regulatory product information states there is no known interaction with other drugs or common supplements. Official labeling does not contain specific prohibitions or warnings regarding the co-consumption of herbal products or dietary supplements.

Q: Is Alvenex a controlled substance?

The medication is not classified as a controlled substance under federal drug schedules. Some formulations may be categorized as a traditional medicine or a prescription medical food product.

Q: What happens if Alvenex is taken with cold or flu medicines?

Official documents state that no cases of significant drug-drug interaction have been reported since the product’s marketing. Consequently, the regulatory label does not list specific medicinal products, including cold or flu medicines, that must be avoided.

Q: Does Alvenex have a risk of allergic reaction, and what are the signs?

The medicine is officially contraindicated for individuals with known hypersensitivity, which is a severe allergy. Signs of an allergic reaction may include rash, hives, shortness of breath, or swelling of the face, lips, tongue, or throat.

Q: What steps are generally taken if someone suspects an overdose of Alvenex?

In the event that an overdose is suspected, the general guidance is to immediately contact a poison control center or seek emergency medical care. Preparation to provide information on the substance taken and the quantity is generally advised.

Q: Does using Alvenex require any special lifestyle changes?

General lifestyle recommendations often complement the medicine’s action to support venous health. These suggestions typically include avoiding prolonged standing, maintaining a healthy weight, and using compression stockings.

Q: Is Alvenex a tablet, capsule, or some other form?

The active ingredient is typically formulated for oral administration. It is available in various forms, such as a tablet or capsule.

Q: Can Alvenex affect blood sugar levels?

Official regulatory documents do not list changes in blood sugar as a common or rare adverse reaction in humans.

Q: Does Alvenex carry a warning related to mental health?

Official regulatory safety summaries state there is no evidence that the active ingredient has any direct influence on mood or mental health.

How should Alvenex be stored and disposed of?

How to Store and Dispose of Alvenex

The storage and disposal requirements for Alvenex (Diosmin) are specified to ensure the product's quality and patient safety. The medication must be stored at a controlled room temperature and should not exceed 30°C to preserve its labeled stability and 3-year shelf life. To prevent accidental ingestion, the product must be kept out of the sight and reach of children at all times.


Handling and Disposal

Official labeling confirms that no special requirements are necessary for the handling or final disposal of unused or expired tablets. Disposal should be carried out according to standard local pharmaceutical waste regulations for non-hazardous medicines.

Storage Requirement Condition
Maximum Temperature 30 C
Child Safety Out of the sight and reach of children

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Alvenex found in:

A-Z Index: